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Cell transformationiruses (HPV) cause cervical cancer. The biological properties of HPV-45, the third
most prevalent high-risk HPV-genotype, are unknown. We demonstrate here that the HPV-45 E7 protein
transforms immortalized NIH3T3 ﬁbroblasts, while mutations in either the conserved LXCXE sequence
(C28G) or the carboxyl-terminus (Δ87LQQLF91) signiﬁcantly abolish this activity. To address the mechanisms
underlying cell transformation by HPV-45 E7, we investigated its impact on the cell cycle. We show that HPV-
45 E7 associates with the hypophosphorylated form of the retinoblastoma protein (pRb) and induces a
signiﬁcant reduction in the pRb half-life which can be blocked by epoxomicin. Moreover, HPV-45 E7 induces
anchorage-independent cell cycle progression of NIH3T3 cells and extends the lifespan of primary human
keratinocytes. HPV-45 E7C28G did not bind pRb and could neither induce pRb-proteolysis nor promote cell
cycle progression. HPV-45 E7Δ87LQQLF91 had intermediate pRb-binding afﬁnity and retained a residual
activity to induce the degradation of pRb but lost the capability to promote cell cycle progression in
suspension. Another carboxyl-terminal mutant, HPV-45 E7Δ81AEDL84, showed a trend to reduced
transforming activity, had reduced pRb-binding activity and lost the capability to induce pRb-degradation;
however, this mutant could induce anchorage-independent cell cycle progression with the same efﬁciency as
HPV-45 E7 wild type. In summary, these data suggest that HPV-45 E7 is a transforming protein and that
abrogation of cell cycle control contributes to its oncogenic potential.
© 2008 Elsevier Inc. All rights reserved.IntroductionHuman papillomaviruses (HPVs) are the main etiological factors
for cervical cancer (zur Hausen, 2002). HPVs are small DNA viruses
that infect basal proliferating epithelial cells of either the skin or
mucosa. More than 120 different HPV genotypes have been described
to date (de Villiers et al., 2004). On the basis of epidemiological and
biochemical data, the mucosal genotypes are subdivided into two
groups. HPVs of the high-risk group, associated with squamous
intraepithelial lesions with a high potential for progression to
squamous cell carcinoma (SCC); and papillomaviruses of the low-
risk group, which cause benign hyperplasias (zur Hausen, 2002;
Muñoz et al., 2004). Highly sensitive PCR-based studies have shown
that over 99% of invasive cervical cancers contain high-risk HPV-DNA
(Walboomers et al., 1999). At present ﬁfteen different high-risk HPV-
types are known (de Villiers et al., 2004). Epidemiologic studiesResearch and Tyrolean Cancer
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l rights reserved.suggest important differences in the prevalence and carcinogenic
potential of the various high-risk HPV-types (Muñoz et al., 2003).
HPV-45 has been reported as the third most prevalent high-risk HPV-
genotype worldwide (Muñoz et al., 2003; Muñoz et al., 2004; Clifford
et al., 2006). This HPV-type was initially isolated from a recurrent
cervical lesion displaying moderate dysplasia with koilocytosis
(Naghashfar et al., 1987). HPV-45 belongs to HPV species 7 in the
genus alpha-papillomavirus (de Villiers et al., 2004) and is phylogen-
etically most closely related with HPV-18 (Naghashfar et al., 1987;
Geisbill et al., 1997).
The initial events of cervical carcinogenesis after viral infection are
not fully understood but, according to the current model, high-risk
HPV-types undergo speciﬁc changes that overcome the transcrip-
tional control of viral gene expression in the infected cells (Zur
Hausen, 1999), leading to deregulated expression of the early viral
genes E6 and E7 (Dürst et al., 1992; Stoler et al., 1992). These genes are
consistently upregulated in human cervical cancer cells and exhibit
the major oncogenic activity of HPVs, as shown for the early viral
proteins of HPV-16 (Crook et al., 1989; Hawley-Nelson et al., 1989;
Münger et al., 1989a,b) and HPV-18 (Barbosa and Schlegel, 1989;
21D. Morandell et al. / Virology 379 (2008) 20–29Hudson et al., 1990). HPV-16 E7 expression alone is sufﬁcient to
immortalize primary human epithelial cells (Halbert et al., 1991;
Reznikoff et al., 1994; Wazer et al., 1995) albeit with reduced
frequency, and to induce invasive cervical cancers in transgenic mice
treated with low doses of estrogen (Riley et al., 2003). These results
are consistent with the strong increase of the HPV-16 E7 protein levels
during early steps of cervical carcinogenesis and with high level
expression of HPV-16 E7 in cervical cancers (Fiedler et al., 2004),Fig. 1. HPV-45 E7 mutations. (A) Alignment of the HPV-16 E7,-18 E7 and -45 E7 amino acid se
between HPV-45 E7 and HPV-18 E7. The location of the cysteines in the pRb-binding site (
residue in the putative pRb-binding site of HPV-45 E7 (C28G) and two zinc-ﬁnger deletion
C28G mutation is located in the conserved LXCXE motif in the unstructured amino-term
(highlighted in blue and red, respectively) are located in carboxyl-terminal helix α1. The N
(C) NIH3T3 cells were transfected with the indicated pcDNA3.1/hygromycin expression vec
Western blotting experiments as indicated. M2-PK served as input control.underlining that E7 plays a major part in the induction of cervical
carcinogenesis. The HPV-45 E7 gene encodes a protein of 106 amino
acids (Ohlenschlager et al., 2006). Like the E7 proteins of HPV-16 and
HPV-18, HPV-45 E7 is localized in both the nucleus and cytoplasm of
the host cells (Fiedler et al., 2004; Fiedler et al., 2005; Greenﬁeld et al.,
1991; Smotkin and Wettstein, 1997), but the biological functions of
HPV-45 E7 are unknown. Three oncogenic domains have been
identiﬁed in HPV-16 E7 (Münger and Howley, 2002). The amino-quences. The identity of amino acids is 46% between HPV-45 E7 and HPV-16 E7 and 78%
LXCXE motif) and the zinc ﬁnger are indicated (asterisk). The mutation of the cysteine
mutations, Δ81AEDL84 and Δ87LQQLF91 are indicated (highlighted in orange). (B) The
inus (indicated by arrow). The two deletion mutations Δ81AEDL84 and Δ87LQQLF91
MR structure of the HPV-45 E7 monomer was taken from Ohlenschlager et al., 2006.
tors and the expression of the HPV-16 E7 and HPV-45 E7 proteins were monitored by
Fig. 2. HPV-45E7 interacts with pRb. (A) HPV-45E7, 45E7 mutants, HPV-16E7, and HPV-
11E7 were produced as GST fusion proteins, bound to resin, and incubated with NIH3T3
cell extracts, as indicated. GST alone was used as negative control. Bound pRb proteins
were analyzed by Western blotting with an anti-pRb monoclonal antibody. GST inputs
were visualized by staining the gel with Coomassie blue stain (bottom panel). Ten
percent of total cellular lysate was included as input control. The binding experiments
were performed three times with similar results. (B) GST pull-down assay performed
with cellular extracts from human HaCaT keratinocytes and GST fusion proteins of HPV-
45E7, 45E7 mutants, HPV-16E7, and HPV-11E7. The experiment was conducted as
described under panel A. (C) U-2OS cells were transiently transfected with expression
vectors for HPV-45 E7 and pRb and co-immunoprecipitations conducted in the lysates
with either αpRb antibodies, αHPV-45 E7 antibodies, preimmunserum of mouse or
goat. The precipitated proteins were analyzed by Western blotting with αpRb and
αHPV-45 E7 antibodies, as indicated. Ten percent of total cellular lysate was loaded as
input control.
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and CR2 of adenovirus E1A and both conserved regions are necessary
for the oncogenic activity of E7. The highly conserved carboxyl-
terminal domain (CR3) of HPV-16 E7 contains a zinc-ﬁnger loop and
contributes to cell transformation (Jewers et al., 1992). According to
the current model, HPV-16 E7 exerts its oncogenic activity by the
binding and functional modiﬁcation of a wide variety of cellular
growth regulatory protein complexes necessary for the oncogenic
potential of the virus (Münger and Howley, 2002; Zwerschke and
Jansen-Dürr, 2000). The best characterized target of HPV-16 E7 is the
negative cell cycle regulator retinoblastoma tumor suppressor protein
(pRb) (Dyson et al., 1989). Themain pRb-binding domain in HPV-16 E7
is localized in the conserved LXCXE motif within CR2 (Lee et al., 1998),
and the C-terminus is also involved in protein–protein interaction
with pRb (Patrick et al., 1994). pRb contains a binding pocket for HPV-
16 E7 (Lee et al., 1998; Hu et al., 1995). The mechanism by which HPV-
16 E7 overrides the repressor function of pRb involves its binding,
which triggers proteasome-dependent degradation of pRb (Boyer et
al., 1996; Demers et al., 1994; Jones et al., 1997; Morozov et al., 1997;
Giarre et al., 2001; Gonzalez et al., 2001) and abolishes the ability of
pRb to bind cellular E2F transcription factors (E2F-1, 2, and 3) (Wu et
al., 1993; Fiedler et al., 2004; Cobrinik, 2005). This abrogates pRb-
mediated repression of E2F-responsive genes and stimulates G1/S-
phase transition (Boyer et al., 1996; Gonzalez et al., 2001; Wu et al.,
1993; Chellappan et al., 1992). The functional inactivation of pRb is
important for the transforming activity of HPV-16 E7 (Phelps et al.,
1992; Ciccolini et al., 1994; Münger and Howley, 2002).
Although a high carcinogenic potential has been reported for HPV-
45 in epidemiological studies (Muñoz et al., 2003; Muñoz et al., 2004;
Clifford et al., 2003; Clifford et al., 2006), and we recently showed that
the HPV-45 E7 protein is highly expressed in HPV-45 DNA positive
cervical cancers (Fiedler et al., 2005, Ressler et al., 2007), the biology of
the early HPV-45 genes has not yet been thoroughly investigated. Here
we present the ﬁrst study on biological properties of HPV-45 E7.
Results and discussion
HPV-45 E7 wild type and mutant proteins
Although epidemiological studies suggest that HPV-45 is an
important HPV-type associated with cervical cancer (Muñoz et al.,
2004; Clifford et al., 2006), no biochemical evidence exists for its
oncogenic activity so far. For this reason, we aimed to analyse the
properties of the HPV-45 E7 protein in cell biological and biochemical
assays. The recently determined protein structure of HPV-45 E7
comprises an unfolded N-terminus (amino acid residues 1–54) and a
well-structured carboxyl-terminal domain forming a unique zinc-
binding fold (Ohlenschlager et al., 2006). Based on the structural
information and amino acid sequence homologies between HPV-45
E7, HPV-18 E7 and HPV-16 E7 (Ohlenschlager et al., 2006; Cole and
Danos, 1987; Phelps et al., 1992; Massimi et al., 1997), three
independent mutations were inserted into HPV-45 E7 (Fig. 1A). The
cysteine residue in the conserved pRb-binding motif (LXCXE) located
in the ﬂexible N-terminus was mutated to glycine (HPV-45 E7C28G).
The homologous mutation in HPV-16 E7 abrogates the transforming
capacity of CR 2 (Phelps et al., 1992). Furthermore, two small deletions,
Δ81AEDL84, and Δ87LQQLF91, respectively, were inserted into the
central helixα1 (amino acid residues 81–93) within the 29 amino acid
long zinc-binding fold in the carboxyl-terminal domain of HPV-45 E7
(Fig. 1B, right panel). Both deletions are located in the hydrophobic
core of the zinc-binding fold (Ohlenschlager et al., 2006), leading to
the shortening of the loop and to a reduction in hydrophobicity. An
obstacle in studying the functions of the carboxyl-terminus of HPV-16
E7 is that mutations in this region often strongly reduce protein
stability (Phelps et al., 1992). To verify that the HPV-45 E7 mutants
produced stable proteins, a Western blot analysis was performed withextracts from NIH3T3 cells transiently expressing the various HPV-45
E7 proteins. It could be demonstrated that the HPV-45 E7 mutants are
detectable at levels similar to those of the HPV-45 E7 and HPV-16 E7
wild-type proteins (Fig. 1C). These ﬁndings indicate that shortening of
the helixα1 in the C-terminal loop of HPV-45 E7 does not signiﬁcantly
impair protein stability.
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We ﬁrst investigated whether HPV-45 E7 can interact with pRb in
vitro using GST pull-down assays (Fig. 2A). Equal amounts of GST and
GST–E7 fusion proteins (Fig. 2A, lower panel) were immobilized on
glutathione–sepharose beads and incubated with NIH3T3 cell protein
extracts. The amount of pRb associated with the E7 proteins was
determined byWestern blot analysis (Fig. 2A, upper panel). HPV-45 E7
bound speciﬁcally to the hypophosphorylated form of pRb and the
binding efﬁciency was slightly higher relative to HPV-16 E7, which has
been shown to associate with pRb (Gonzalez et al., 2001). These two
high-risk HPV E7 proteins bound stronger to pRb than low-risk HPV-
11 E7, which has been described as a low-afﬁnity pRb-binding protein
(Münger et al., 1989a,b). Next we determined the ability of different
HPV-45 E7 mutants to associate with pRb. The point mutant HPV-45
E7C28G showed virtually no binding to pRb in this assay, indicating
that the cysteine residue in the LXCXE motif confers the majority of
the pRb-binding afﬁnity to HPV-45 E7, although, in the case of HPV-16
E7 another binding site with low afﬁnity to pRb located in the
C-terminal region has been reported (Patrick et al., 1994). To analyse
whether the carboxyl-terminus of HPV-45 E7 plays any role for pRb-
binding, we determined the pRb-binding afﬁnity of the two carboxyl-
terminal HPV-45 E7 mutants in the GST pull-down assay. While
Δ87LQQLF91 bound to pRb with medium afﬁnity relative to the HPV-
45 E7 wild-type protein the Δ81AEDL84 mutant showed a still
stronger reduction in the pRb-binding afﬁnity. To corroborate the
data, the GST pull-down experiments were repeated with protein
extracts from human HaCaT keratinocytes (Fig. 2B). In these assays,
HPV-45 E7 wild type bound speciﬁcally to the hypophosphorylated
form of pRb, HPV-45 E7C28G showed virtually no binding to pRb and
the two carboxyl-terminus HPV-45 E7 mutants Δ87LQQLF91 and
Δ81AEDL84 bound to pRb with reduced afﬁnity. These data indicate
that HPV-45 E7 speciﬁcally binds to the hypophosphorylated form of
pRb, and that the LXCXE motif in the ﬂexible amino-terminal region is
the major pRb-binding site. Moreover, HPV-45 E7 has another pRb-
binding domain in the central helixα1within the zinc-binding loop in
the carboxyl-terminal domain.
Identifying HPV-45 E7 as a high-afﬁnity pRb-binding protein in
vitro, we conﬁrmed the interaction between HPV-45 E7 and pRb in E7-
expressing human cells. To do this, co-immunoprecipitation experi-
ments were performed in lysates from U-2OS cells transiently
transfected with CMV-promoter driven expression vectors for HPV-
45E7 and human pRb. To counteract the degradation of pRb, the
proteasome activity was blocked by the addition of LLnL 3 h before cell
lysis. As shown in Fig. 2C, pRb was speciﬁcally co-precipitated with E7
in extracts from E7-expressing U-2OS cells using anti-HPV-45 E7
antibodies but not control antibodies. Antibodies to pRb speciﬁcally
co-precipitated HPV-45 E7 with pRb from extracts of E7-expressing
U-2OS cells, whereas immunoprecipitation of pRb and E7 was not
achieved with control antibodies (Fig. 2C). These ﬁndings were
corroborated in co-immunoprecipitations conducted with protein
extracts from C33A cervical cancer cells transiently expressing HPV-
45E7. In these experiments, HPV-45 E7 was speciﬁcally co-precipi-
tated with α-pRb antibodies and pRb with α-HPV-45 E7 antibodies
(data not shown).
In summary, these data suggest that HPV-45 E7 can form a
complex with pRb in lysates of tumour cells. The results are in
agreement with previous studies which showed that HPV-16 E7 and
other viral oncoproteins like SV40 large tumor antigen and adenovirus
E1A bind to the hypophosphorylated pRb form (Demers et al., 1994;
Boyer et al., 1996; Ludlow et al., 1989; Imai et al., 1991; Raychaudhuri
et al., 1991). The Rb tumor suppressor has multiple phosphorylated
forms that runwith various mobilities on SDS/PAGE and the biological
activity of pRb is controlled by cell cycle-dependent phosphorylation/
dephosphorylation (Ludlow et al., 1989). The fastest-migrating form is
the hypophosphorylated form that shows up in the cell after M-phaseand becomes phosphorylated at the transit from G1 to S. The
hypophosphorylated form of pRb acts in limiting cell proliferation
by inhibiting G1/S cell cycle transition and one mechanism proposed
for the inactivation of pRb by viral oncoproteins is that these proteins
bind to pRb and thereby releasing free E2F transcription factors which
induces S-phase (Raychaudhuri et al., 1991). Thus our data suggest
that the binding of HPV-45 E7 to hypophosphorylated pRb contributes
to cell cycle progression.
HPV-45 E7 induces proteasome-dependent degradation of pRb
To address the questionwhether HPV-45 E7 exhibits the activity to
induce the proteolytic degradation of pRb, we performedWestern blot
analysis to assess pRb steady-state levels in cells transiently expres-
sing the HPV-45 E7 proteins (Fig. 3A). Expression of HPV-45 E7 wild
type reduced the pRb steady-state levels while the HPV-45 E7 C28G
mutation within the LXCXE motif resulted in failure to reduce Rb
steady-state levels (Fig. 3A, compare lanes 2 and 3). The expression of
HPV-45 E7 Δ87LQQLF91 induced also a reduction of the pRb steady-
state levels while the other carboxyl-terminal mutation, HPV-45 E7
Δ81AEDL84, did not induce reduced pRb steady-state levels (Fig. 3A,
compare lanes 2–5). As shown for HPV-16 E7 (Fig. 3A, lane 6; Boyer et
al., 1996; Helt and Galloway, 2001), predominantly the steady-state
level of the hypophosphorylated pRb formwas reduced in the HPV-45
E7 expressing cells.
To determine whether HPV-45 E7 affects the protein stability of
pRb, pRb-degradation assays were performed with HPV-45 E7 wild
type and mutants (Figs. 3B–H). NIH3T3 cells were transiently
transfected with the empty vector pCDNA3Hygro (mock) (Fig. 3B)
and pCDNA3Hygro-HPV-45 E7 (Fig. 3C), respectively, and the turnover
of pRbwas analysed. Cycloheximide (CHX) was added to block cellular
protein synthesis, ruling out any inﬂuence of altered protein synthesis
on the pRb steady-state levels andmetabolic half-life. Cells were lysed
in SDS sample buffer following a time course and the pRb levels
analyzed by 8% SDS-PAGE and Western blotting using anti-pRb
antibodies (Figs. 3B and C). We found a fast turnover of the higher
molecular weight hyperphosphorylated pRb form coming along with
increasing amounts of the hypophosphorylated form, which was
highly stable in the mock transfected cells (Fig. 3B). The intensities of
both the hyper- and hypophosphorylated pRb bands were measured
densitometrically and the half-life (T1/2) calculated by semi-logarith-
mic plotting of the intensity of the bands against the CHX incubation
time (0, 3 and 6 h). Plots of the means from three independent
experiments are shown. The half-life of pRb was 16 h 20 min (±4 h
15 min) (x ̄±SD, n=3) in empty vector containing NIH3T3 cells (Fig. 3B)
and 5 h 12 min (±1 h 13 min) (x̄±SD, n=3) (Pb0.05, HPV-45 E7 vs
empty vector) when HPV-45 E7 was expressed (Fig. 3C). The pRb half-
life was similar in HPV-45 E7 and HPV-16 E7 (4 h 12 min (±38 min)
(x̄±SD, n=3) (Pb0.05, with HPV-16 E7 vs empty vector) expressing
cells (compare Figs. 3C and D). Cells transiently expressing the pRb-
non-binding mutant HPV-16 E7C24G served as another negative
control (Fig. 3E). When the assay was performed with the HPV-45 E7
mutants C28G, Δ81AEDL84 and Δ87LQQLF91, we found no signiﬁcant
alterations in the half-life of pRb in cells expressing the three HPV-45
E7mutants relative to E7-nonexpressing cells (Figs. 3B, F–H), although
the HPV-45 E7 Δ87LQQLF91 mutant retained a considerable residual
activity to induce pRb-degradation. In summary, these data indicate
that HPV-45 E7 can efﬁciently induce pRb-degradation, and this
activity is impaired in the CR2mutant C28G as well as by mutations in
the carboxyl-terminal zinc-binding loop, underlining the speciﬁcity of
this HPV-45 E7 activity. The failure to induce pRb-degradation
correlates with lost pRb-binding afﬁnity of HPV-45 E7C28G (Figs. 2A
and B); however, also the two carboxyl-terminal mutants, Δ81AEDL84
and Δ87LQQLF91, which still bound to pRb even though with reduced
binding afﬁnity, lost the ability to signiﬁcantly reduce the half-life of
pRb. This suggests that HPV-45 E7-induced pRb protein degradation
Fig. 3. HPV-45 E7 induces destruction of pRb. (A) Reduced pRb steady-state levels in HPV-45 E7 expressing cells. NIH3T3 cells were transiently transfected with empty vector (mock)
or HPV E7 expression vectors as indicated. Cell lysates were separated on 8% and 12.5% PAGES and the pRb steady-state level (hyperphosphorylated Rb-pp and hypophosphorylated
Rb) monitored in Western blotting experiments (top panel). E7 and M2-PK (loading control) protein level were also analysed (lower panels). Shown is a representative Western blot
from 5 different experiments. (B–H) HPV-45 E7 reduces the half-life of pRb. NIH3T3 cells were transiently transfected with empty vector or HPV E7 expression vectors as indicated.
Protein biosynthesis was blocked by addition of 100 μg/ml cycloheximide (CHX) and cells were harvested at the indicated time intervals (t, hours) in 1.5× SDS-Laemmli-sample buffer
and the level of pRb (hyperphosphorylated Rb-pp and hypophosphorylated Rb) determined byWestern blotting (top panels). M2-PK served as input control (lower panels). The blot
was developed using a chemiluminescence system, pRb bands (from time points 0, 3 and 6 h) were scanned from low exposures and densitometrically analyzed. The arithmetic mean
of three experiments is shown (right panels). HPV E7 protein expression was monitored by Western blotting (see Panel A).
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proteins but also on additional function(s) contained in the carboxyl-
terminus of the HPV-45 E7 protein. Similar mutations in the LXCXE
motif also prevented HPV-16 E7 from reducing the half-life of pRb
(Helt and Galloway, 2001); however, in contrast to a HPV-16 E7
C-terminal zinc-ﬁnger loop mutation, Δ79LEDLL83 (Massimi et al.,
1997), which permitted destabilization of pRb (Helt and Galloway,
2001), both HPV-45 E7 C-terminal mutants employed in this study
either prevented or reduced the destabilization of pRb (Fig. 3),
suggesting differences in the C-terminal domain between both high-
risk E7 proteins. This might reﬂect the assignment of the two HPV-
types to different phylogenetic groups: HPV-16 belongs to HPV species
9 and is only remotely related to HPV-45 which is assigned to HPV
species 7 (De Villiers et al., 2004).
To investigate whether the proteasome plays a role in HPV-45 E7-
induced pRb-destruction, we added the proteasome inhibitors
epoxomicin (Epo) and LLnL, respectively, for 3 h together with CHX
to supernatants of NIH3T3 cells and analysed the pRb levels in the celllysates by Western blotting. One representative example of 3
independent experiments is shown in Fig. 4. The steady-state level
of pRb was signiﬁcantly increased by the effects of epoxomicin as well
as LLnL in NIH3T3 cells transiently expressing HPV-45 E7 (Fig. 4A).
While a slight proteasome inhibitor-dependent increase in the pRb
levels was also detectable in HPV-45 E7Δ87LQQLF91 expressing cells
(Fig. 4C), no proteasome inhibitor-dependent increase in the pRb
levels was found in HPV-45 E7C28G (Fig. 4B) and HPV-45 E7
Δ81AEDL84 expressing cells (Fig. 4D). Together these ﬁndings indicate
that, similar to HPV-16 E7 (Boyer et al., 1996; Jones and Münger, 1997;
Helt and Galloway, 2001), the proteasome plays a part in HPV-45 E7
induced degradation of pRb. Moreover, the failure of the HPV-45 E7
mutants to destabilize pRb suggests that the LXCXEmotif in conserved
region 2 as well as the hydrophobic core of the helix α1 in the
carboxyl-terminal zinc-ﬁnger loop are important for HPV-45 E7-
induced proteasome-dependent destruction of pRb. This is in keeping
with the inability of these HPV-45 E7 mutants to signiﬁcantly reduce
the half-life of pRb (see Fig. 3). A role of the proteasome in HPV-16 E7-
Fig. 4. HPV-45 E7 induced degradation of pRb is blocked by proteasome inhibitors. (A–
E) NIH3T3 cells were transiently transfected with empty vector or HPV-45 E7
expression vectors as indicated. CHX and the proteasome inhibitors epoxomicin (Epo)
and LLnL were added 18 h after transfection to the cell culture supernatants as
indicated. Cells were harvested 3 h later in 1.5× SDS-Laemmli-sample buffer. pRb levels
were determined by Western blotting (upper panels). M2-PK served as input control
(lower panels). One set of representative Western blots from three different
experiments is shown.
Fig. 5. HPV-45 E7-expressing cells enter S-phase in suspension culture. Exponentially
growing cultures of NIH 3T3 cells were transfected with the indicated pcDNA3.1/
Hygromicin HPV-45E7 and empty expression vectors. Polyclonal cell lines were
generated by selection under hygromycin. The resulting polyclonal HPV E7 expressing
NIH3T3 cell lines were grown in DMEM+10% FCS, trypsinized and seeded in aliquots on
dishes that were coated with agarose to prevent attachment and incubated for 20 h
under these conditions. Cells were harvested in Nicoletti buffer and stained with
propidium iodide. The cell cycle proﬁle was analysed by FACS analysis and the S-phase
evaluated using MODFIT software. Bars represent mean values of the S-phase±SD from
three experiments (⁎⁎Pb0.01).
25D. Morandell et al. / Virology 379 (2008) 20–29induced degradation of pRb is established (Boyer et al., 1996; Jones
and Münger, 1997; Giarre et al., 2001; Helt and Galloway, 2001); HPV-
16 E7 targets pRb for proteasome-dependent degradation, which
impairs pRb-dependent proliferation arrest in the G1 phase of the cell
cycle. The abundance of pRb is inversely correlated with E7
oncoprotein expression in high-grade cervical lesions and the pRb
levels are very low in invasive cervical carcinomas (Fiedler et al.,
2004), underlining the importance of HPV-16 E7-induced degradation
of pRb in cervical carcinogenesis. HPV-16 E7 can directly interact with
the S4 ATPase subunit of the 19S regulatory complex of the 26S
proteasome and it was suggested that polyubiquitination may be not
needed for degradation (Berezutskaya and Bagchi, 1997). However,
HPV-16 E7 can also induce polyubiquitination and proteolysis of pRb
through the ubiquitin/proteasome pathway (Wang et al., 2001), and a
role of the cullin 2 ubiquitin E3-ligase complex in this process was
recently described (Huh et al., 2007). While this study showed that
amino-as well as carboxyl-terminal sequences (79LEDLL83) of HPV-16
E7 contribute to pRb interaction, we demonstrate here that the CR2
and carboxyl-terminal sequences of HPV-45 E7 are important for pRb-
interaction and -degradation. However, it is presently not known
whether HPV-45 E7 binds to cullin 2 complexes, and the role of the
ubiquitin/proteasome pathway for HPV-45 E7-induced degradation of
pRb warrants further study.
HPV-45 E7 induces anchorage-independent cell proliferation in rodent
NIH3T3 cells and lifespan extension in primary human keratinocytes
The retinoblastoma protein is a major negative regulator of G1-S
cell cycle transition, which is frequently inactivated in cervical cancer.
HPV-16 E7 allows resting rodent cells to initiate DNA replication by
overcoming several forms of G0 and G1 arrest induced by distinct
antiproliferative signals (Münger and Howley, 2002). One experi-
mental condition known to arrest untransformed cells in the G1 phase
of the cell cycle is to cultivate them in suspension (Guadagno et al.,
1993). HPV-16 E7 has been shown to induce anchorage-independentcell proliferation (Schulze et al., 1998). Thus, it was of interest to
determine whether HPV-45 E7 induced inactivation of pRb leads to
anchorage-independent cell proliferation. To do this, NIH3T3 cells
were transfected with pCDNA3Hygro expression vectors for HPV-45
E7 wild-type, the three HPV-45 E7 mutants and empty vector (Mock)
and selected under hygromycin. All colonies that arose under selection
were pooled to generate polyclonal cell lines and expression of the
HPV-45 E7 proteins was monitored by Western blotting (see above,
Figs. 1C and 3A). We studied the ability of the HPV-45 E7-expressing
cells to enter S-phase when they were cultured in suspension on
agarose-coated dishes by measuring their DNA content in FACS
experiments (Fig. 5). While cells expressing HPV-45 E7 wild-type
showed a signiﬁcant increase in S-phase cells relative to cells with
empty vector, the S-phase fraction of the cells expressing the pRb-
nonbinding and -nondegrading mutant HPV-45 E7C28G was not
altered relative to mock treated cells. This suggests that the C28G
mutation abrogates the anchorage-independent cell cycle progression
promoting activity of HPV-45 E7. HPV-45 E7Δ87LQQLF91 was also
strongly impaired in its capability to induce S-phase in suspension.
This indicates that the deletion of the hydrophobic sequence
87LQQLF91 in the carboxyl-terminus of HPV-45 E7 abolishes the
activity to induce anchorage-independent cell proliferation, which
correlates with the impaired capability of this mutant to bind pRb and
to induce its degradation. This result couples HPV-45 E7-induced pRb-
destabilization with the abrogation of loss of adhesion-induced cell
cycle arrest and is the ﬁrst indication that the carboxyl-terminus of a
high-risk HPV E7 protein is important for the induction of anchorage-
independent cell proliferation. HPV-45 E7Δ81AEDL84 could induce
anchorage-independent cell cycle progression with the same efﬁ-
ciency as HPV-45 E7 wild type (Fig. 5). Although the deletion of
81AEDL84 led to reduced pRb-binding and abrogation of the
capability to induce pRb-degradation, this mutant retained the
capability to drive the cells into S-phase in suspension. Thus HPV-45
E7Δ81AEDL84 remains wild type in an activity which is sufﬁcient for
HPV-45 E7 to induced S-phase. It is possible that this activity of HPV-
45 E7Δ81AEDL84 is caused by the physical interaction with pRb (see
Fig. 2) and disruption of pRb-E2F complexes which can enhance G1/S-
phase progression as shown for HPV-16 E7 (Münger and Howley,
2002). It is, however, presently not known whether the reduced pRb-
binding activity of HPV-45 E7Δ81AEDL84 (see Figs. 2A and B) is
sufﬁcient to disrupt pRb/E2F complexes. Together these ﬁndings
demonstrate that the activity of HPV-45 E7 to induce anchorage-
independent proliferation in NIH3T3 cells can be attributed to the
conserved LXCXE motif in CR2 as well as to the hydrophobic sequence
Table 1









HPV-45 E7 WT +++ +++ +++ +++
HPV-45 E7C28G – – – –
HPV-45 E7ΔLQQLF ++ + – –
HPV-45 E7ΔAEDL + – +++ ++
+++, wild type level of activity; ++, medium activity; +, low activity; –, no activity.
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loop, and suggest that the capability of HPV-45 E7 to override cell
cycle arrest induced by loss of adhesion is related to its ability to
bind to pRb as well as to induce the degradation of pRb. The most
homologous mutation to Δ87LQQLF91 made in HPV-16 E7 is
Δ79LEDLL83 (Massimi et al., 1997). HPV-16 E7Δ79LEDLL83 is
strongly impaired in its ability to induce the S-phase following
DNA-damage induced cell cycle arrest whereas the activity of HPV-
16 E7Δ79LEDLL83 in anchorage-independent cell cycle progression
is unknown. In contrast to the C-terminal HPV-45 E7 mutant, HPV-
16 E7Δ79LEDLL83 is still capable to efﬁciently induce pRb-
destruction (Helt and Galloway, 2001), indicating a difference
between the carboxyl-terminal domains of the two high-risk HPV
E7 proteins. As mentioned above HPV-16 belongs to HPV species 9
and is only remotely related to HPV-45 which is assigned to HPV
species 7 (De Villiers et al., 2004), and the identity of amino acids
between HPV-45 E7 and HPV-16 E7 is only 46%. Nevertheless, the
data shown in this study suggest that shortening of the hydro-
phobic amino acid sequence in the central helix α1 within the
zinc-binding fold in the carboxyl-terminal domain of HPV-45 E7 as
well as HPV-16 E7 abrogates the pro-proliferative potential of both
E7 proteins.
Inactivation of the pRb/p16INK4a pathway is important for the
induction of life-span extension in human keratinocytes (Münger and
Howley, 2002). Here we addressed the question whether HPV-45 E7
has the potential to extend the lifespan of primary human
keratinocytes. After retroviral infection with pLXSN-HPV-45 E7,
pLXSN-HPV-45 E7C28G, pLXSN-HPV-45 E7Δ87LQQLF91, and the
empty vector pLXSN as negative control, the E7 genes were equally
expressed as detected by RT-PCR (data not shown). Following two
independent infections with each recombinant amphotropic retro-
virus, keratinocytes were cultured in selective medium and their
lifespan was determined. As expected, control keratinocytes contain-
ing empty vector ceased proliferating after a few population
doublings (18 days), while HPV-45 E7 wild type expressing
keratinocytes formed colonies and showed continuous proliferation
beyond day 55 (21 PDLs). Cells expressing the two transformation-
deﬁcient HPV-45 E7 mutants C28G and Δ87LQQLF91, which are
either strongly impaired (C28G) or reduced (Δ87LQQLF91) in their
ability to degrade pRb, stopped proliferation and underwent a
senescence phenotype after 25 (C28G) and 30 days (Δ87LQQLF91),
respectively. Thus, HPV-45 E7 has the capability to speciﬁcally extend
the lifespan of primary human keratinocytes, as known for HPV-16
E7 (Hawley-Nelson et al., 1989; Münger et al., 1989a,b; Halbert et al.,
1991; Reznikoff et al., 1994).Fig. 6.HPV-45 E7 has transforming activity. Immortalized NIH3T3 cells were transfected
with the HPV E7 pcDNA3.1/hygromycin expression vectors as indicated. After two
weeks of selection under hygromycin, arising colonies were pooled and analysed by
growth in soft agar (GISA) experiments. The graphs represent the mean from three
experiments, with the respective standard deviations (±SD). Pb0.05 was taken as the
level of signiﬁcance (⁎), (Mock= 0 colonies). The expression of the HPV E7 proteins was
controlled by Western blotting (see Figs. 1C, 3A and data not shown).HPV-45 E7 is a transforming protein and mutations in CR 2 as well as
carboxyl-terminal zinc-ﬁnger loop abrogate this activity
Aware of the strong effects of HPV-45 E7 on pRb-degradation, cell
cycle progression, and lifespan extension in primary keratinocytes,
we analysed whether HPV-45 E7 possess transforming properties. To
do this, immortalized NIH3T3 cells were transfected with various
HPV-45 E7 genes inserted in the pCDNA3Hygro expression vector as
indicated and selected under hygromycin. Empty vector and an HPV-
16 E7 expression vector were employed as negative and positive
control, respectively. Arising colonies were pooled to generate
polyclonal HPV-45 E7 proteins expressing cell lines (see Fig. 1C).
Subsequently, growth in soft agar (GISA)-experiments were carried
out to analyse the transforming potential of the various E7 proteins
(Fig. 6). It was found, that HPV-45 E7 had the same strong capability
as HPV-16 E7 to induce transformation of NIH3T3 cells, which
acquired the ability to grow in an anchorage-independent manner in
soft agar. Empty vector containing (Mock) cells formed no colonies in
soft agar. Mutagenesis of the cysteine residue in the LXCXE domain
(HPV-45 E7C28G) strongly reduced the transforming function of
HPV-45 E7, as only a few colonies appeared after three weeks of
GISA. Deletion of the hydrophobic amino acid sequence Δ87LQQLF91
in the carboxyl-terminal domain of HPV-45 E7 also resulted in a
signiﬁcantly reduced efﬁciency of transformation relative to the
HPV-45 E7 wild-type protein. Less pronounced were the effects of
the deletion of the less hydrophobic C-terminal amino acid sequence
81AEDL84, although the transformation rate was reduced by
approximately 40%. These ﬁndings suggest that HPV-45 E7 has
strong transforming activity in immortalized mouse ﬁbroblasts, and
identiﬁes the conserved cysteine in the LXCXE motif in CR2 as well
as the highly hydrophobic amino acid sequence Δ87LQQLF91 in the
central helix α1 in the carboxyl-terminal domain as necessary for
cell transformation. Homologous mutations to the highly conserved
HPV-45 E7 LXCXE motif as well as the less conserved LQQLF motif
(Ullman et al., 1996; see also Fig. 1), also confer transformation
deﬁciency in HPV-16 E7 (Phelps et al., 1992; Massimi et al., 1997),
underlining the importance of these two motifs for the transforming
functions of HPV E7 protein.
In conclusion, the present study demonstrates that human
papillomavirus type 45 E7 is a potent transforming protein in
vitro, which binds to pRb and can induce pRb-degradation,
anchorage-independent cell cycle progression in rodent cells and
lifespan extension in primary human keratinocytes. Two domains
necessary for the transforming activity of HPV-45 E7 were identiﬁed
in this study, conserved region 2 and the carboxyl-terminal zinc-
binding fold. The mutation of the conserved cysteine residue to
glycine in the LXCXE pRb-binding motif abrogated the transforming
activity mediated by conserved region 2 (see Table 1). The solution
of the structure of the carboxyl-terminal zinc-binding fold of HPV-
45 E7 (Ohlenschlager et al., 2006) enabled us to insert targeted
mutations into the central helix α1 within the 29 amino acid long
zinc-binding fold. One small deletion inserted in the hydrophobic
core of the zinc-binding fold (Δ87LQQLF91), which leads to the
shortening of the loop and to a reduction in hydrophobicity,
conferred transformation deﬁciency. This is a new high-risk HPV
27D. Morandell et al. / Virology 379 (2008) 20–29E7 mutant, which binds pRb with reduced afﬁnity relative to E7
wild type but is impaired to induce pRb-destabilization. This mutant
couples HPV-45 E7 mediated pRb-degradation with the abrogation
of cell cycle arrest induced by loss of adhesion and with cell
transformation (Table 1).
Together with the available epidemiological data (Muñoz et al.,
2003; Muñoz et al., 2004; Clifford et al., 2006), the biological
properties of the HPV-45 E7 protein determined here underline the
important role of HPV-45 in cervical carcinogenesis and contribute
to a better understanding of the oncogenic properties of this virus.
HPV-45 is the third most prevalent high-risk type found in cervical
carcinoma with a worldwide incidence between 4–9% (Muñoz et
al., 2003; Clifford et al., 2006), and a signiﬁcantly higher prevalence
in Western Africa (Muñoz et al., 2004; Bosch et al., 1995).
Moreover, HPV-45 has the third highest SCC/low-grade squamous
intraepithelial lesion (LSIL) prevalence ratio (Clifford et al., 2005),
and a comparison of the HPV-type-distribution across cervical
lesions of increasing severity, has shown that HPV-types 16, 18 and
45 are signiﬁcantly more common in SCC than in high-grade
squamous intraepithelial lesions (HSIL), whereas the reverse is true
for other HPV-types (Clifford et al., 2003; Clifford et al., 2006).
These epidemiological data underline the importance of HPV-45 in
the risk of progression to cervical cancer. Previous research has
mainly focused on HPV-16 (HPV species 9) and HPV-18 (HPV
species 7) as the two most prevalent high-risk HPV-types. While
the molecular and clinical characteristics of other HPV genotypes
belonging to HPV species 9 and 7 may be similar to HPV-16 and
-18, further research is needed to fully clarify the similarities and
differences within the high-risk HPV group, especially to better




pCMVFlag-HPV-45 E7 was a gift of Barbara Fitzky (Amynon
Biotech GmbH, Innsbruck, Austria). The HPV-45 E7 cDNAwas inserted
as EcoRI/XhoI fragment into the bacterial GST expression vector
pGEX4T-1, generating pGEX4T-1-HPV-45 E7. Mutations were inserted
into HPV-45 E7 using Gene-Editor In Vitro Site-Directed Mutagenesis
Kit (Promega, Mannheim), generating the plasmids pGEX4T-1-HPV-
45 E7C28G, pGEX4T-1-HPV-45 E7Δ81AEDL84, pGEX4T-1-HPV-45
E7Δ87LQQLF91. All HPV-45 E7 cDNAs were ampliﬁed by PCR and
inserted as EcoRV/BamHI fragments into pCDNA3Hygro, generating
pCDNA3Hygro-HPV-45E7, pCDNA3Hygro-HPV-45 E7C28G, pCDNA3-
Hygro-HPV-45 E7Δ81AEDL84, pCDNA3Hygro-HPV-45 E7Δ87LQQLF91.
All HPV-45 E7 cDNAs were inserted as XhoI/BamHI fragments into the
retroviral vector pLXSN, generating pLXSN-HPV-45E7, pLXSN-HPV-45
E7C28G, pLXSN-HPV-45 E7Δ87LQQLF91. pLXSN-HPV-16 E7 was a gift
from Massimo Tommasino (Lyon, France).
Cell culture
The human U-2OS osteosarcoma cells and the cervical cancer cells
C33A were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM),
10% fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomy-
cin, and 2 mM L-glutamine. Primary human keratinocytes were
cultured together with irradiated NIH3T3 used as feeder layer in a
medium containing 3 parts of Ham's F12 medium and 1 part of
DMEM and supplemented with 2.5% FCS, 5 μg/ml insulin, 10 ng/ml
EGF, 8.4 ng/ml cholera toxin, 0.4 μg/ml hydrocortisone. Feeder layer
was prepared by irradiating NIH3T3 (137C; 25Gy). NIH3T3 cells were
grown in DMEM containing 4.5 g/l of glucose and supplemented
with 10% CS. Phoenix cells were grown in DMEM supplemented with
10% FCS.Western blot analysis
Western blot was performed as described (Mannhardt et al., 2000).
Brieﬂy, cells were lysed in SDS sample buffer. Lysates were separated
either on 12.5% or 8% SDS-PAGES and transferred to a PVDFmembrane
(NEN, Boston). The membrane was blocked in PBS/0.2% Tween20/5%
milk powder and incubated with the given 1st antibodies (polyclonal
goat anti-HPV-45 E7 antibodies (Fiedler et al., 2005); monoclonal anti-
pRb antibodies (BD Pharmingen #554136, Vienna) for 1 h. After
washing, a peroxidase-conjugated anti-IgG (Promega, Mannheim)
was applied. The membrane was washed and the bound antibodies
visualized using the chemiluminescence Western blotting detection
system (NEN, Boston).
Co-immunoprecipitation
U-2OS or C33A cells were transfected with pCDNA3Hygro-HPV-
45E7 and/or pCMV-pRB as indicated using the Effectene transfection
kit (Qiagen, Hilden). The proteasome activity was blocked by addition
of LLnL (100 μM) 3 h before harvesting. Extracts from 5×106 cells were
prepared in lysis buffer (1.5 mM KH2PO4, 8.1 mM Na2HPO4 [pH 7.4],
2.7 mM KCl, 150 mM NaCl, 0.2 mM phenylmethylsulfonyl ﬂuoride
[PMSF], 1 mMNaF, 100 μM LLnL, 1 mM dithiothreitol [DTT], 0.1% Triton
X-100, protease inhibitor mix no. 1836170 [Roche Diagnostics]) and
subjected to immunoprecipitation with goat anti-HPV-45 E7 anti-
bodies (Fiedler et al., 2005), monoclonal anti-human pRb antibodies
(Pharmingen #554136, Vienna) or with mouse and goat control
antibodies. ProteinA/G beads were added and 3 h later washed three
times in lysis buffer. Precipitated proteins were visualized by Western
blotting using anti-HPV-45 E7 and anti-pRb antibodies.
GST pull-down assays
GST pull-down assays were conducted as described (Mannhardt et
al., 2000). Brieﬂy, GST fusion proteins were expressed in bacteria from
the pGEX-4T-1 vectors. The GST fusion proteins were puriﬁed and 2 μg
or 5 μg loaded onto glutathione–Sepharose 4B beads and incubated
with cellular extracts either fromNIH3T3 or HACaT. After washing, the
speciﬁcally bound proteins were analyzed by Western blotting.
Protein half-life determination and analysis of proteasome-dependent
destruction
Protein-stability assays were conducted as described (Santer et al.,
2006). NIH3T3 cells were transiently transfected with pCDNA3Hygro-
HPV-45E7 vectors. The protein biosynthesis was blocked by incuba-
tionwith 100 μg/ml fresh cycloheximide (Sigma, Vienna). After 20min
of preincubation, the cells were harvested at speciﬁc time intervals in
1.5×SDS Laemmli sample buffer. Cellular lysates were separated on an
8% PAGE and the pRb expression levels determined by Western
blotting. The blot was developed using a chemiluminescence system,
pRb bands were scanned from low exposures and densitometrically
analyzed. The half-life of the pRb was calculated by semi-logarithmic
plotting of the intensity of the densitometrically analyzed bands
against the incubation time. When indicated, the cells were incubated
for 3 h with LLnL (100 μM) or with epoxomicin (10 μM) to block the
proteasome (Meng et al., 1999).
Growth in soft agar assay
These assays were performed by seeding cells in 35-mm-diameter
dishes onto an underlayer of 0.5% low-gelling agarose in growth
medium. Cells were plated in medium containing 0.28% SeaPlaque
agarose and fed every three days with growth medium essentially as
described (Nauenburg et al., 2001). Colonies were allowed to grow for
2–3 weeks and scored microscopically.
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NIH3T3 cells infected with the empty vector pCDNA3Hygro or the
HPV-45 E7 expression vectors pCDNA3Hygro-HPV-45E7, pCDNA3Hy-
gro-HPV-45 E7C28G, pCDNA3Hygro-HPV-45 E7Δ81AEDL84, and
pCDNA3Hygro-HPV-45 E7Δ87LQQLF91 were selected in monolayers
under hygromycin (150 μg/ml) in Dulbecco's modiﬁed essential
medium (DMEM) supplemented with 10% calf serum (DMEM/10%
CS) to generate polyclonal cell lines. Cells were then trypsinized and
grown in DMEM/10% CS in suspension on plates coated with DMEM
containing 0.9% agarose, as described previously (Schulze et al., 1998).
Cell cycle proﬁle of PI stained nuclei (Nicoletti et al., 1991) was
measured by FACS analysis (FACSCalibur, Becton Dickinson). Cell cycle
distributionwas analysed using Mod-Fit software (Becton Dickenson).
Retroviral infections and keratinocyte lifespan extension
Primary human keratinocytes were infected using high-titer
retroviral supernatants generated by transient transfection of phoenix
cells as previously described (Pear et al., 1993), with pLXSN vectors
containing or not E7 genes, and were then selected for 2 weeks in the
growth medium containing 100 μg/ml G418. Primary human kerati-
nocytes were further passaged in keratinocyte growth medium.
Phoenix cells were transfected using CalPhos mammalian transfection
kit (Clontech, Lyon).
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